Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Phase II trial evaluating satraplatin in patients with metastatic breast cancer begins
December 8th, 2005
GPC Biotech, AG, (GPCB) announced that a phase II study evaluating the company's lead drug candidate, satraplatin, in patients with metastatic breast cancer who have received no more than one prior chemotherapy treatment regimen has opened for accrual. The study is being managed by US Oncology. Satraplatin is currently in a phase III registrational trial as a second-line chemotherapy treatment for patients with hormone-refractory prostate cancer. The company is also opening new clinical studies to explore the potential of satraplatin in a number of additional tumor types. The phase II study in metastatic breast cancer is an open-label, multicenter...
Source: Women's Health Weekly (2005-12-08)
|
